Infasurf and curosurf: theoretical and practical considerations with new surfactants

Type II pneumocytes, normally responsible for surfactant production and release, are insufficiently formed and differentiated in the premature infant born before 34 weeks' gestation. Without an adequate amount of pulmonary surfactant, alveolar surface tension increases, leading to collapse and...

Full description

Saved in:
Bibliographic Details
Published inThe journal of pediatric pharmacology and therapeutics Vol. 8; no. 2; pp. 97 - 114
Main Authors Nguyen, Thuy N, Cunsolo, Stephanie M, Gal, Peter, Ransom, J Laurence
Format Journal Article
LanguageEnglish
Published United States Pediatric Pharmacy Advocacy Group 01.04.2003
Subjects
Review
poractant
beractant
calfactant
surfactant
Online AccessGet full text

Cover

More Information
Summary:Type II pneumocytes, normally responsible for surfactant production and release, are insufficiently formed and differentiated in the premature infant born before 34 weeks' gestation. Without an adequate amount of pulmonary surfactant, alveolar surface tension increases, leading to collapse and decreased lung compliance. Pulmonary surfactants are naturally occurring substances made of lipids and proteins. They lower surface tension at the interface between the air in the lungs, specifically at the alveoli, and the blood in the capillaries. This review examines the relative benefits of the two most recently marketed surfactants, calfactan (Infasurf) and poractant alfa (Curosurf).
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1551-6776
2331-348X
DOI:10.5863/1551-6776-8.2.97